List of Excipients in Branded Drug INSPRA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Pfizer Laboratories Div Pfizer Inc	INSPRA	eplerenone	0025-1710	CELLULOSE, MICROCRYSTALLINE
Pfizer Laboratories Div Pfizer Inc	INSPRA	eplerenone	0025-1710	CROSCARMELLOSE SODIUM
Pfizer Laboratories Div Pfizer Inc	INSPRA	eplerenone	0025-1710	FERRIC OXIDE RED
Pfizer Laboratories Div Pfizer Inc	INSPRA	eplerenone	0025-1710	FERRIC OXIDE YELLOW
Pfizer Laboratories Div Pfizer Inc	INSPRA	eplerenone	0025-1710	HYPROMELLOSE
Pfizer Laboratories Div Pfizer Inc	INSPRA	eplerenone	0025-1710	LACTOSE

INSPRA (Eplerenone) Excipient Strategy and Commercial Opportunities

Last updated: August 24, 2026

INSPRA is the branded eplerenone tablet marketed by Pfizer for hypertension and post-myocardial-infarction heart failure. Its commercial protection is largely exhausted: eplerenone has generic competition, and the principal U.S. compound patent expired in 2022. The strongest current opportunities are therefore in low-cost generic manufacturing, differentiated solid oral dosage forms, adherence-oriented packaging, regional registration, and specialty formulations rather than conventional patent exclusivity.

What is INSPRA and which excipients does it use?

INSPRA contains eplerenone, a selective aldosterone receptor antagonist. The U.S. product is supplied as immediate-release film-coated tablets in 25 mg and 50 mg strengths. The FDA-approved labeling identifies the following inactive ingredients:

Component	Likely function
Lactose monohydrate	Diluent and compression aid
Microcrystalline cellulose	Diluent, binder, and tablet-structure agent
Croscarmellose sodium	Superdisintegrant
Hypromellose	Film-forming coating polymer
Sodium lauryl sulfate	Wetting agent and dissolution aid
Talc	Glidant and anti-adherent
Titanium dioxide	Opacifier and coating pigment
Ferric oxide pigments	Tablet-color system

The precise excipient composition can vary by market and manufacturing site. The reference product's formulation establishes a regulatory benchmark but does not prevent a generic manufacturer from using a different excipient system if the finished product satisfies applicable quality, bioequivalence, stability, and labeling requirements. [1]

What formulation attributes matter for eplerenone?

Eplerenone is a small-molecule, immediate-release drug. The main development issues are:

1. Content uniformity at the 25 mg strength.
2. Rapid and reproducible disintegration.
3. Adequate dissolution across physiological pH conditions.
4. Moisture and physical stability during storage.
5. Acceptable tablet size and swallowability.
6. Control of polymorphic or solid-state variation.
7. Compatibility between the drug substance and surfactant, lubricant, coating, or alkaline excipients.

The reference formulation uses a conventional excipient architecture. A competing product does not need to replicate the exact ingredient list, but an excipient change can affect dissolution, impurity formation, tablet hardness, friability, and bioequivalence performance.

What patents protect INSPRA and when did eplerenone lose exclusivity?

The principal U.S. patent associated with eplerenone was U.S. Patent No. 5,981,744, assigned to Pharmacia, later part of Pfizer. The patent covered eplerenone and related steroidal compounds. Its U.S. term expired in 2022, subject to the applicable patent-term adjustment and regulatory exclusivity framework. [2]

Protection category	Status
Eplerenone compound patent	Expired in the United States
FDA small-molecule exclusivity	Expired
Immediate-release tablet exclusivity	No current branded exclusivity barrier
Biosimilar exclusivity	Not applicable
Generic competition	Established
Formulation-patent barrier	No verified current U.S. barrier identified from the cited sources

The patent estate is therefore weak as a current U.S. blocking position. Value may remain in unexpired foreign patents, manufacturing know-how, regulatory data packages, trademarks, and market-specific registrations. Those rights must be reviewed jurisdiction by jurisdiction because eplerenone patent terms and generic approval timing have varied across countries.

What is the Orange Book status of INSPRA?

The FDA Orange Book historically listed INSPRA under eplerenone and identified patent information associated with the reference product. The Orange Book is the controlling U.S. source for listed patents and regulatory exclusivity associated with approved small-molecule products. [2]

Because eplerenone is an established generic product, the commercial significance of Orange Book listings is limited compared with a product facing active Paragraph IV litigation. A current diligence review should distinguish:

• Historical patents that have expired.
• Any listed patent with remaining term.
• Pediatric exclusivity, if applicable.
• NDA supplements that may have generated separate patent listings.
• Approved strengths and dosage forms covered by the reference NDA.

A patent listed in the Orange Book does not establish that all formulation, manufacturing, or method-of-use claims remain enforceable. Term, claim scope, prosecution history, terminal disclaimers, and litigation outcomes control the practical risk.

Which companies challenged INSPRA, and what is the litigation status?

Generic eplerenone competition developed through abbreviated new drug applications. Generic applicants could use Paragraph III certifications for patents they accepted as valid and unexpired or Paragraph IV certifications asserting that listed patent claims were invalid, unenforceable, or not infringed. The competitive market now demonstrates that eplerenone generic entry occurred.

No active, high-value U.S. litigation campaign should be assumed solely from the historic existence of Paragraph IV filings. A live litigation assessment requires current PACER, district-court, Federal Circuit, and Orange Book review. Historic ANDA disputes have limited commercial relevance where the asserted patents have expired and generic products are already approved.

What does a generic launch scenario look like?

For a new U.S. eplerenone applicant, the likely pathways are:

Launch pathway	Commercial implication
Standard ANDA after patent expiry	Lowest litigation risk; price competition is high
Paragraph III ANDA	Appropriate only where a listed patent remains relevant
Paragraph IV ANDA	Limited value unless an enforceable listed patent blocks entry
505(b)(2) application	Potentially useful for a novel dosage form, liquid, modified release, or clinically differentiated product
Authorized-generic or contract-manufacturing supply	Lower development risk but weaker product differentiation

The principal launch risk is not patent infringement. It is price erosion, procurement concentration, manufacturing reliability, FDA inspection performance, and the ability to secure pharmacy, hospital, and payer contracts.

What excipient strategy is most attractive for generic eplerenone?

A conventional formulation is the lowest-risk option. The development team should first target an excipient system that closely matches the reference product's performance, while retaining freedom to optimize cost and manufacturability.

Strategy 1: Reference-like immediate-release tablet

This approach uses lactose or another established diluent, microcrystalline cellulose, croscarmellose sodium, a controlled lubricant system, and a conventional film coat.

Advantages include:

• Familiar regulatory profile.
• Straightforward tablet development.
• Established supplier base.
• Lower scale-up risk.
• Simplified comparative dissolution work.

The principal weakness is limited differentiation. Multiple generic suppliers may offer essentially interchangeable products, forcing competition on cost and supply performance.

Strategy 2: Lactose-free formulation

A lactose-free product could use mannitol, dibasic calcium phosphate, starch, or a co-processed filler-binder system. The opportunity is strongest in markets or channels where lactose intolerance, excipient avoidance, or institutional formulary requirements influence purchasing.

The formulation must address:

• Powder flow.
• Compression behavior.
• Disintegration time.
• Moisture sensitivity.
• Tablet weight and size.
• Any change in dissolution caused by altered wettability or porosity.

A lactose-free label claim can support a marketing distinction, but it is unlikely to justify a major price premium without a targeted commercial channel.

Strategy 3: Direct-compression platform

A direct-compression process can reduce equipment, labor, solvent, and drying costs. It is attractive for high-volume generic supply if the drug substance has adequate flow and blending behavior.

Key risks include segregation at the low-dose 25 mg strength, poor content uniformity, capping, and sensitivity to lubricant overmixing. A co-processed excipient may improve robustness, but it can raise material cost and create supplier-concentration risk.

Strategy 4: Wet-granulated tablet

Wet granulation can improve blend uniformity and compressibility. It is useful where the active pharmaceutical ingredient has poor flow or where the target tablet requires high mechanical strength.

Its disadvantages are higher processing cost, greater exposure to heat and moisture, longer cycle times, and more opportunities for impurity growth. A low-moisture or solvent-minimized process may be preferable if stability data show sensitivity.

Strategy 5: Fast-dispersing or orally disintegrating tablet

An orally disintegrating eplerenone product could target patients with dysphagia, elderly patients, or post-hospitalization populations. The format may support a 505(b)(2) strategy if the product has a meaningful clinical or administration advantage.

Technical barriers include the drug's taste, tablet friability, moisture uptake, packaging requirements, and dose loading. Unit-dose blister packaging is likely to be more suitable than standard high-density polyethylene bottles.

Strategy 6: Pediatric liquid or multiparticulate product

A liquid suspension, solution, or sprinkle product could expand administration options. Eplerenone's low aqueous solubility and taste may require pH adjustment, suspending agents, wetting agents, flavor systems, and preservative control.

This route has a higher development burden than a standard tablet. It may be commercially attractive only where a defined pediatric, geriatric, or dysphagia population exists and a regulatory pathway supports differentiated labeling.

What formulation patents could protect an eplerenone product?

A new formulation may generate patentable subject matter around:

• A specific particle-size distribution.
• A defined polymorphic or amorphous form.
• Stabilized solid dispersions.
• A pH-modified formulation.
• A controlled-release matrix.
• An orally disintegrating tablet.
• A liquid suspension with improved physical stability.
• A taste-masking system.
• A low-impurity manufacturing process.
• A packaging system that controls moisture or light exposure.

Patent strength depends on whether the claimed feature produces an unexpected technical effect. A claim directed only to replacing lactose with mannitol, or changing one conventional disintegrant for another, may face obviousness and enablement challenges. Stronger claims generally link the excipient system to a measurable result, such as improved dissolution under a defined condition, enhanced stability, reduced impurity formation, or improved bioavailability.

A formulation patent does not automatically block a conventional generic tablet. It must cover the accused product's composition, process, use, or performance-linked structure.

What manufacturing and intellectual-property barriers affect commercial entry?

Manufacturing barriers

The most important manufacturing issues are:

• Reliable API supply.
• Control of particle size and solid state.
• Uniform distribution at the 25 mg strength.
• Consistent film-coating color.
• Dissolution reproducibility after scale-up.
• Impurity control during granulation and storage.
• Validation of cleaning procedures for steroidal compounds.
• Supplier qualification for pigments, surfactants, and coating polymers.

Eplerenone manufacturers should avoid unnecessary dependence on a single source for sodium lauryl sulfate, coating materials, or specialty co-processed excipients. A second-source strategy can be more valuable commercially than a minor formulation novelty.

Geographic coverage

The commercial opportunity differs by jurisdiction:

Market	Main opportunity
United States	Low-cost ANDA supply, hospital contracting, alternate dosage forms
European Union	National reimbursement and tender participation; country-specific generic pricing
Japan	Local regulatory and commercial partnerships
Emerging markets	Reliable supply, lower-cost excipients, simplified packaging
Gulf and Latin America	Registration efficiency and distributor access

Patent exhaustion, regulatory exclusivity, data-protection periods, and local manufacturing rules must be assessed separately. A U.S. patent expiry does not establish freedom to operate in Europe, Japan, China, or other markets.

How does INSPRA compare with competing aldosterone antagonists?

Product	Active ingredient	Dosage-form profile	Commercial position
INSPRA	Eplerenone	Immediate-release tablets	Selective aldosterone antagonist; generic competition
Aldactone	Spironolactone	Tablets and other market-specific forms	Older, lower-cost competitor with broader generic penetration
Finerenone products	Finerenone	Immediate-release tablets	Newer nonsteroidal competitor with differentiated clinical positioning

Eplerenone's commercial advantage over spironolactone is its greater selectivity, which can support use where endocrine adverse effects are a concern. Its disadvantage is generic price pressure and competition from newer products with differentiated heart-failure and chronic-kidney-disease positioning.

A reformulated eplerenone product must therefore offer more than cosmetic excipient changes. The strongest commercial cases involve administration convenience, a defined adherence problem, a pediatric or dysphagia population, or a cost advantage supported by manufacturing scale.

What revenue exposure and commercial opportunities remain?

Branded INSPRA revenue is exposed to generic substitution and formulary pressure. Public company disclosures may report the product within broader cardiovascular or pharmaceutical segments rather than as a separately audited line item. Product-level revenue should not be inferred without a specific company filing.

Current opportunities include:

1. High-volume generic supply with competitive cost of goods.
2. Regional licensing of approved eplerenone products.
3. Contract manufacturing for distributors and hospital systems.
4. Lactose-free or excipient-reduced tablets.
5. Unit-dose blister packaging for adherence and institutional use.
6. Orally disintegrating or sprinkle products.
7. Pediatric or dysphagia-oriented dosage forms.
8. Dual sourcing and shortage-prevention contracts.
9. API and finished-dose supply into countries with limited competition.
10. 505(b)(2) development for a clinically differentiated delivery system.

The most defensible near-term strategy is a reference-like generic with a robust supply chain and a selective excipient improvement. A novel dosage form has greater upside but requires clinical, regulatory, and commercial evidence that the delivery benefit offsets development cost.

Key Takeaways

• INSPRA contains eplerenone in 25 mg and 50 mg immediate-release film-coated tablets.
• The reference formulation uses conventional excipients, including lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, hypromellose, sodium lauryl sulfate, talc, titanium dioxide, and iron-oxide pigments.
• The principal U.S. eplerenone patent, U.S. Patent No. 5,981,744, expired in 2022.
• Biosimilar risk is not relevant because eplerenone is a small molecule.
• Conventional generic entry is primarily a cost, quality, supply, and contracting problem rather than a patent problem.
• The strongest formulation opportunities are lactose-free, orally disintegrating, pediatric, sprinkle, and stability-enhanced products.
• A formulation patent is more valuable when it claims a demonstrated technical effect rather than a routine excipient substitution.
• Geographic patent and regulatory status must be reviewed country by country.
• The commercial ceiling for an undifferentiated generic is limited by established generic competition and pressure from spironolactone and finerenone.

FAQs

Can a new eplerenone excipient combination receive patent protection?

Yes. Protection may be available if the combination is novel, nonobvious, enabled, and linked to a measurable technical benefit such as improved stability, dissolution, bioavailability, or administration.

Is a lactose-free INSPRA generic commercially attractive?

It can be attractive in targeted channels, but lactose removal alone is unlikely to support a significant premium. The product should combine the excipient distinction with reliable supply, compact tablets, and a clear customer segment.

Would an eplerenone oral suspension require a new FDA application?

A materially different liquid product may require a 505(b)(2) application or another regulatory pathway rather than a conventional ANDA, depending on the reference product, formulation, labeling, and reliance strategy.

Does eplerenone have biosimilar competition?

No. Eplerenone is a chemically synthesized small molecule regulated through the generic-drug framework, not the biosimilar pathway.

What is the highest-value commercial improvement for a generic eplerenone tablet?

For a conventional product, the highest-value improvement is usually manufacturing reliability and low cost of goods. For a differentiated product, an orally disintegrating, sprinkle, or pediatric formulation has greater potential than a routine excipient substitution.

References

1. U.S. Food and Drug Administration. (2023). INSPRA (eplerenone) tablets, prescribing information. FDA.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
3. U.S. Patent No. 5,981,744. (2000). 19-nor steroid derivatives as aldosterone receptor antagonists. United States Patent and Trademark Office.
4. U.S. Food and Drug Administration. (2024). Approved drug products database and abbreviated new drug application resources. FDA.
5. DailyMed. (2024). Eplerenone tablet labeling. National Library of Medicine.